The post A legendary Bitcoin whale just made a $3.8B bet on Ethereum – Details appeared on BitcoinEthereumNews.com. Journalist Posted: September 1, 2025 ETH: Strength in numbers Whale transaction counts for transfers over $1 million spiked through August, coinciding with ETH’s climb above $4,300. Big players have been actively repositioning, adding momentum. Source: Santiment At the same time, ETH’s Futures Open Interest surged past $70 billion before settling near $60 billion. Spot and derivatives markets are aligning behind Ethereum, with whales providing liquidity on one end and traders increasing exposure on the other. Source: CoinGlass ETH holds steady At press time, Ethereum traded near $4,390, moving sideways after its strong rally earlier in August. The daily chart showed little momentum, with the RSI indicating a neutral zone. The MACD also pointed lower, so short-term momentum had slowed even as prices stayed stable. Source: TradingView This period of consolidation showed ETH was pausing after recent gains, while whales continued to buy into the dips. The market looks to be in a cooling phase for now, but ready for its next move. Next: Metaplanet’s Bitcoin strategy on the ropes after 54% decline – Details Source: https://ambcrypto.com/a-legendary-bitcoin-whale-just-made-a-3-8b-bet-on-ethereum-details/The post A legendary Bitcoin whale just made a $3.8B bet on Ethereum – Details appeared on BitcoinEthereumNews.com. Journalist Posted: September 1, 2025 ETH: Strength in numbers Whale transaction counts for transfers over $1 million spiked through August, coinciding with ETH’s climb above $4,300. Big players have been actively repositioning, adding momentum. Source: Santiment At the same time, ETH’s Futures Open Interest surged past $70 billion before settling near $60 billion. Spot and derivatives markets are aligning behind Ethereum, with whales providing liquidity on one end and traders increasing exposure on the other. Source: CoinGlass ETH holds steady At press time, Ethereum traded near $4,390, moving sideways after its strong rally earlier in August. The daily chart showed little momentum, with the RSI indicating a neutral zone. The MACD also pointed lower, so short-term momentum had slowed even as prices stayed stable. Source: TradingView This period of consolidation showed ETH was pausing after recent gains, while whales continued to buy into the dips. The market looks to be in a cooling phase for now, but ready for its next move. Next: Metaplanet’s Bitcoin strategy on the ropes after 54% decline – Details Source: https://ambcrypto.com/a-legendary-bitcoin-whale-just-made-a-3-8b-bet-on-ethereum-details/

A legendary Bitcoin whale just made a $3.8B bet on Ethereum – Details

ETH: Strength in numbers

Whale transaction counts for transfers over $1 million spiked through August, coinciding with ETH’s climb above $4,300. Big players have been actively repositioning, adding momentum.

Source: Santiment

At the same time, ETH’s Futures Open Interest surged past $70 billion before settling near $60 billion.

Spot and derivatives markets are aligning behind Ethereum, with whales providing liquidity on one end and traders increasing exposure on the other.

Source: CoinGlass

ETH holds steady

At press time, Ethereum traded near $4,390, moving sideways after its strong rally earlier in August.

The daily chart showed little momentum, with the RSI indicating a neutral zone. The MACD also pointed lower, so short-term momentum had slowed even as prices stayed stable.

Source: TradingView

This period of consolidation showed ETH was pausing after recent gains, while whales continued to buy into the dips. The market looks to be in a cooling phase for now, but ready for its next move.

Next: Metaplanet’s Bitcoin strategy on the ropes after 54% decline – Details

Source: https://ambcrypto.com/a-legendary-bitcoin-whale-just-made-a-3-8b-bet-on-ethereum-details/

Market Opportunity
NEAR Logo
NEAR Price(NEAR)
$1.728
$1.728$1.728
-1.03%
USD
NEAR (NEAR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26